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Abstract
Intense research using vertebrate model organisms has gained considerable knowl‐
edge regarding the  origin  of  peripheral  neurons,  such as  neural  crest  and cranial
placodes  induction  and  diversification.  However,  early  development  in  human
embryos has remained largely uncharacterized, despite the roles the neural crest, cranial
placodes and their derivatives play in several pathologies. The in vitro systems based
on the differentiation of human pluripotent stem cells (hPSCs) strikingly recapitulate
embryonic development in a dish. Extensively proved for the neurogenesis in the central
nervous system (CNS) in the last 15 years, novel in vitro differentiation strategies were
recently  designed  for  the  generation  of  peripheral  nervous  system  (PNS)-related
populations. It is the case of human neural crest, cranial placodes, cranial sensory and
autonomic neurons, and enteric neurons. These novel models are equally important for
enlightening  the  human early  development  and for  developing new tools  for  the
modern  medicine.  Better  understanding  of  the  programs  for  specification  and
maturation of the multitude of peripheral neurons is a major challenge confronting
developmental and stem cell researchers in years to come.
Keywords: neural crest, cranial placodes, sensory ganglia, sympathetic ganglia, enter‐
ic ganglia, human embryo, pluripotent stem cells, peripheral neuropathies
1. Introduction
Human pluripotent stem cells (hPSCs), whether derived from the inner cell mass of an embryo
at the blastocyst stage (human embryonic stem cells, hESCs) [1], or generated via reprogram‐
ming  of  differentiated  somatic  cells  (human  induced  PSC,  hiPSCs)  [2],  can  self-renew
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indefinitely  in  culture  while  maintaining  the  ability  to  generate  all  the  cell  types  in  an
organism.
The potential of using hPSCs for generating neural cells has been extensively exploited during
the last 15 years. The derivation of central nervous system (CNS) cells was among the first
differentiation protocols developed in the hESC field [3,4]; nowadays, efficient protocols are
available for generating neuroepithelial cells [5], spinal cord motor neurons [6], midbrain
dopaminergic neurons [7], and cortical neurons [8,9], among many others, valid from both
hESCs and hiPSCs.
The effort to generate specific cell types was guided by the knowledge gained from studies on
model organisms, as well as from the previous mouse embryonic stem cell differentiation
studies. The cell biology of neurogenesis has been studied in most detail in CNS, but much
progress has been achieved also for the peripheral nervous system (PNS) development
(reviewed in [10–13]). PNS neurons are categorized into two anatomical and functional classes:
sensory and autonomic neurons.
The sensory neurons are afferent neurons that relay information from a number of specific
structures (including Merkel’s discs, Meissner’s, Pacini’s and Ruffini’s corpuscles, Golgi
tendon organs, and muscle spindles) to the CNS. Accordingly, proprioceptive neurons provide
spatial information regarding position and movement, mechanoceptive neurons mediate
touch, nociceptive neurons respond to painful stimuli or itch, and thermoceptive neurons relay
information regarding temperature. These neurons form cranial ganglia (trigeminal, geniculate,
petrosal, nodose, and others), and dorsal root ganglia (DRG), a metameric series of ganglia next
to the spinal cord.
The autonomic neurons are largely efferent motor neurons that carry information from the CNS
to the various organs of the body, providing involuntary control of the visceral organs. The
autonomic PNS consists of three major components: the sympathetic (SyNS) and parasympa‐
thetic (PSNS) nervous systems, which function together to maintain body homeostasis, and
the enteric nervous system (ENS), which controls gut motility. SyNS controls the involuntary
activities that occur under stressful “fight or flight” conditions, while PSNS, in general,
promotes the visceral activities characteristic of periods of peace and relaxation. Axons from
CNS neurons situated in vegetative centers in brainstem and spinal cord project and synapse
with the ganglionic cell bodies located paravertebrally, along the body axis, for SyNS, in
sympathetic ganglia (SG) or inside the target organs (for PSNS) as parasympathetic ganglia,
distributed all over the body. ENS is the largest component of the autonomic nervous system
and comprises local neural circuits in the gastrointestinal tract consisting of sensory, inter-,
and motor neurons, capable of an autonomous control, without CNS inputs. Sympathetic
neurons are noradrenergic (the most) or cholinergic (few, e.g., sudomotor). Parasympathetic
neurons are cholinergic (the most) or adrenergic (few). Enteric neurons, whose number
surpasses that of spinal cord neurons, have remarkable cytoarchitecture and neurotransmitter
diversity, including serotonin (5-hydroxytryptamine, 5-HT), GABA (γ-aminobutyric-acid-
positive), and nitric-oxide-synthase (NOS)-positive neurons.
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The peripheral neurons originate from neural crest and cranial placodes, two transient
embryonic epithelia generated in early embryogenesis at the junction between CNS primordia
and non-neural ectoderm. These ectodermal structures are notable for their ability to transform
into mesenchymal-like cells, migrate extensively along highly stereotypic pathways and
differentiate into numerous derivatives, according to the environmental influences encoun‐
tered during their journey and at their final sites. In addition to sensory and autonomic neurons
of the PNS, they form many other derivatives, including, from the neural crest, Schwann cells
and satellite glia, melanocytes, endocrine cells, chondroblasts, osteoblasts, odontoblasts and
smooth muscle cells, among others [10–12], and from placodes, sense organ cells and neuro‐
endocrine cells in the head [13].
Neural crest and placode development are multistep processes whose main features are
conserved across all vertebrate groups. Section 2 summarizes, in a pan-vertebrate model, the
current understanding of neural crest and placode induction, specification, migration, and
diversification, pointing on the major signaling molecules and transcription factors that act in
each stage.
During the past ten years, much progress has been made in elucidating the mechanisms that
orchestrate the differentiation of neural crest and placode cells toward the multitude of
neurons forming the PNS. It is the case of sensory neurogenesis and autonomic neurogenesis
(sympathetic, parasympathetic, and enteric) in various vertebrate models, which are briefly
reviewed in Section 3.
Understanding the developmental ontogeny of the diverse peripheral neural populations
provides an essential framework for designing rational approaches towards hPSC directed
differentiation. Recently, protocols for efficient differentiation of hPSCs toward neural crest
cells (NCCs), cranial placode cells (CPCs), neural crest-derived sensory neurons, neural crest-
derived enteric neurons, and placode-derived sensory neurons have been reported, and are
briefly reviewed in Section 4.
The expression profiles reported from the in vitro differentiation protocols and confirmed in
human embryos are combined in an in vitro model proposed in Section 5. As a lot little is known
about the specification mechanisms in human embryo comparing with animal models, these
in vitro approaches can gain further insights into the early human development. As the iPSC
technology has opened unprecedented opportunities for medicine, current challenges and
future avenues in the development of novel therapeutic strategies for PNS diseases are also
discussed.
2. Peripheral nervous system development in a pan-vertebrate model
2.1. Origins: neural border, neural crest, and cranial placodes
PNS originates early in development from epiblast, in close connectivity with the CNS and
epidermal development. At the beginning of gastrulation, a median domain named neural
ectoderm starts to form in the anterior part of the embryo, which eventually generates the neural
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plate, the neural tube, and the entire CNS; a new territory is formed between the future neural
and non-neural ectodermal domains, named the neural border domain (reviewed in [11–16]).
The induction of both neural and neural border domains is established in all vertebrates by a
complex interplay of signaling pathways such as fibroblast growth factors (FGFs), bone
morphogenic proteins (BMPs), and Wingless and Int proteins (WNTs), although the sources
of these signals and their inhibitors may vary between species. At the anterior end of the
embryo, the inhibitors DKK1 (dickkopf 1, a WNT inhibitor) and noggin (a BMP inhibitor)
suppress posterior signals and pattern the neural ectoderm, leading to the formation of the
anterior neural plate and tube. In the lateral part of the embryo, increased activity of WNT and
BMP specifies the non-neural ectoderm. The neural border originates within a zone exposed
to intermediate levels of FGFs and WNTs, as well as to BMP inhibitors. The neural border cells
turn on the expression of a new set of transcription factors, named the neural border specifiers,
which include Tfap2, Msx, Zic, Gbx2, Pax3/7, Dlx5/6, Gata2/3, Foxi1/2, and Hairy2 (reviewed in
[12–16]) (Figure 1).
Figure 1. Induction of neural crest and preplacodal domain. (A and B) Prior and during gastrulation, FGF, BMP, and
WNT initiate the differentiation of epiblast (A) medially into neural ectoderm and laterally into non-neural ectoderm.
The neural border is induced between the non-neural and neural ectoderm (B). Prior and during neurulation, FGF,
BMP, and WNT signaling at the neural border domain induces the neural crest (C), while attenuation of BMP and
WNT signaling in the presence of FGF initiates the preplacode induction. In the medial part, the inhibition of BMP and
WNT signaling in the neural ectoderm domain defines clear borders of the neural plate (red), which starts to form the
neural tube and future central nervous system. In the lateral part, high levels of BMP and WNT define the epidermal
domain (blue). BMP, bone morphogenic protein; FGF, fibroblast growth factor; NC ↑, activation; ↓, inhibition.
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At subsequent stages, the neural plate closes to form the neural tube (a process named
neurulation). As a consequence, the border territory elevates, forming the dorsal aspect of the
opposing neural folds and of the new forming neural tube. Different signaling pathways
together with the neural plate border specifiers act to segregate the neural border domain
medially into the neural crest and laterally into the preplacodal domain. Neural crest is induced
by the presence of FGF, BMP, and WNT activity, while FGF activity and inhibition of BMP and
WNT signals in this stage induce the formation of the preplacodal domain. The emergence of
the neural crest is marked by the expression of a new set of genes named neural crest specifiers:
FoxD3, Ets1 and Snai1/2, Twist and Sox8/9/10. The emergence of the preplacodal domain is
marked by the expression of the placodal specifiers Six1, Eya1/2, and Irx1 (reviewed in [12–16])
(Figure 1).
During neurulation and somitogenesis, the anterior-posterior (A/P) patterning of the neural
plate/tube and of the associated neural crest and preplacodal domains takes place. As in the
neural tube, the A/P patterning of the neural crest and placode domains is regulated by the
major signaling pathways: FGFs, BMPs, WNTs, sonic hedgehog (SHH), Notch, and retinoic
acid (RA). Their combined action further segregates both neural crest and preplacodal domains
(reviewed in [12–16], Figure 2).
Figure 2. Regionalization and specification of neural crest and preplacode domains.
Cranial neural crest anterior to somite 1 contributes to the formation of the head (including
bone, cartilage, connective tissue, teeth, and cranial ganglia (the last together with cranial
placodes). Posterior to somite 1, vagal, trunk, and sacral neural crests are formed. Between
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somite 1–7, vagal neural crest gives rise to the ENS and cardiac outflow tracts. Between somite
7–28, trunk neural crest differentiates into DRG, SG, and norepinephrine-producing cells in
the adrenal gland. Posterior to somite 28, sacral neural crest provides part of the ENS of the
distal gut. Melanocytes and Schwann cells are generated from neural crest of all A/P levels
(Figure 2).
Following the A/P patterning in the developing embryonic head, the preplacodal domain is
divided into The anterior, posterior, and intermediate domains (Figure 2). Anterior domain
comprises the adenohypophyseal, olfactory, and lens placodes. The posterior domain com‐
prises the otic and epibranchial placodes. Between the anterior and posterior placodes devel‐
ops the trigeminal placode. With the exception of the adenohypophyseal and lens placodes,
all other cranial placodes give rise to sensory neurons of their associated sensory structures.
The otic placode generates the sensory neurons of its associated vestibulocochlear (VIIIth)
ganglion, and epibranchial placode gives rise to the sensory neurons of the geniculate, petrosal,
and nodose ganglia. The trigeminal placode gives rise to the sensory neurons of the ophthalmic
and maxillo-mandibular divisions of the trigeminal ganglion.
2.2. Migration: epithelial-to-mesenchymal transition and stereotypical pathways
After the neural crest and placodes are specified and patterned, their cells acquire mesenchy‐
mal properties and migratory morphology and commence migration. The epithelial-to-
mesenchymal transition (EMT) was intensively studied in neural crest. Most of the work has
focused on the adhesive changes that enable cells to delaminate. Cadherins are thought to be
central to this process, a switch between type 1 cadherins (Ecad and Ncad) and type 2 cadherins
(Cad7 and Cad11) taking place in migratory cells.
The neural crest specifiers activate the EMT effector program, which allows the neural crest
cells to delaminate from the neural folds/tube and become a migratory cell type, but also to
maintain them in a proliferative state. Extracellular signals such as FGF2, neuregulin, neuro‐
trophin 3 (NT3), and epithelial growth factor (EGF) help migratory cell survival and/or
proliferation and may act as instructive cues [16,17]. Migratory NCCs are complex from a
regulatory viewpoint, as they are constantly exposed to different environmental signals and
are also starting to differentiate into diverse derivatives.
Additionally, different signaling systems are involved in the guidance of neural crest migration
and the establishment of the correct migratory pathways [17]. For example, the melanocyte
precursors follow a dorsolateral migratory stream, under the epidermis, while the sensory and
autonomic precursors from trunk neural crest follow a ventromedial pathway, between the
neural tube and the developing somites. Sympathetic progenitors express the chemokine
receptor CXCR4, which is responsible for the directed migration toward the dorsal aorta,
where the chemoattractant SDF-1 is produced [18].
Next section briefly describes the differentiation steps of the NCCs and CPCs that are fated to
become sensory neurons, as well as of the NCCs fated for autonomic neurons. However,
Pluripotent Stem Cells - From the Bench to the Clinic312
understanding the programs of neural crest diversification is a major challenge confronting
development biologists in years to come.
3. Peripheral neurogenesis
3.1. Sensory neurogenesis
Cranial sensory neurons are derived mainly from trigeminal and epibranchial placodes and
fewer from cranial neural crest, while the neurons forming the DRGs are derived solely from
trunk neural crest. Specification of sensory neurogenic lineages has been better documented
for the trunk neural crest (reviewed in [10, 11]). Each functional type of sensory neuron is
characterized by its own unique set of receptors and ion channels, and their differentiation
depends on unique sets of transcription factors.
A crucial molecular handle for analyses of sensory neuron development was provided by the
discovery that functionally related neuronal subtypes require specific neurotrophic factors.
Trophic factor signaling has long been recognized, particularly the neurotrophin ligand/
receptor components: nerve growth factor (NGF)/TrkA, brain derived neurotrophic factor
(BDNF)/TrkB, and NT-3/TrkC [19,20]. Premigratory NCCs delaminated at different time
points, and sensory neurons are generated in a number of waves that derive from temporally
distinct NCCs that enter in the ventromedial pathway and arrest migration adjacent to the
neural tube, generating DRGs [21]. Large-diameter TrkC/TrkB+ proprio- and mechanorecep‐
tive neurons are produced first, while small-diameter TrkA+ nociceptive neurons are subse‐
quently generated. Later, boundary cap cells also generate a small population of TrkA+
nociceptive sensory neurons.
The first two waves of NCC differentiation are regulated by Neurogenin1 (Ngn1) and Neuro‐
genin2 (Ngn2). Neurogenin-1 and Neurogenin-2 are potent promoters of sensory specification
and can be detected in a subset of proliferative migrating cells [22]. Ngn1 appears to play a
predominant role in formation of small-diameter nociceptive (TrkA+) neurons with a minor
requirement in the formation of large-diameter mechanoreceptor (TrkB+) and proprioceptive
(TrkC+) neurons. In contrast, Ngn2 plays a transient role in formation of large-diameter
mechanoreceptor (TrkB+) and proprioceptive (TrkC+) neurons; Ngn2+ cells also contribute to a
small but significant fraction of nociceptive (TrkA+) neurons.
The subsequent transition of neurogenic progenitors into post-mitotic neurons involves up-
regulation of Brn3a and Islet1, as well as down-regulation of factors that maintain NCC
multipotency, such as Sox10 and FoxD3 [23–25]. Brn3a and Islet1 also direct the expression of
transcription factors important for sensory neuron maturation, such as the Runx family. Runx1
is critical for the continuing differentiation of nociceptive neurons, while Runx3 primarily
regulates proprioceptive maturation [21,26,27].
The signaling pathways and transcriptional changes that occur during sensory neuron
specification have been well documented [28]. Many of the extrinsic and intrinsic cues that act
in the neural crest specification act also in sensory neurogenesis. WNT/β-catenin signaling acts
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on sensory specification at the premigratory stage and during later stages of neuronal devel‐
opment [29].
During their early maturations stages, the sensory neurons begin to grow neurites that
fasciculate with outgrowing spinal motor axons in the forming ventral root en route to the
periphery or project centrally into the spinal cord via the dorsal root and innervate CNS targets.
Somite-derived patterning cues direct the stereotyped position of early sensorimotor projec‐
tions into the periphery and coordinate alignment with the developing vertebrae [30]. At
further stages of maturation, peripheral innervation targets, central neurons, and associated
glia produce neurotrophic factors that direct the development of receptive neuronal subtypes.
Proper neurotrophic signaling is crucial also for sensory neuron survival and synapse
formation [30].
3.2. Sympathetic neurogenesis
Sympathetic neurons are derived from trunk neural crest (Figure 2). Major differentiation steps
and gene regulators acting on the way between neural crest progenitors and mature sympa‐
thetic neurons have been identified in several vertebrate species (reviewed in [31]).
The initial sympathetic differentiation depends on signals from the ventral neural tube and
The notochord, as well as the environment surrounding the dorsal aorta. Sympathetic
progenitors migrate along the ventro-medial path and reach the dorsal aorta, initially forming
a continuous sympathetic chain that subsequently segregates into discrete ganglia. The ventro-
medial path is shared with the DRG precursors, and the sympathetic precursors pass through
the DRG primordia to reach the sites of primary sympathetic ganglia. The aorta-derived signals
have been identified as members of the family of BMPs, which have an essential role in
sympathetic neuron development [32]. Accordingly, migrating sympathetic progenitors
express the chemokine receptor CXCR4 [18]. The cells then undergo a second migration to
para-aortic sites, where secondary sympathetic ganglia are formed. Some of these cells from
the primary sympathetic ganglia migrate deeper into the embryo toward the kidney, where
they differentiate into predominantly neuro-endocrine cells (chromaffin cells) of the adrenal
gland.
The BMP-induced differentiation involves the sequential onset of expression of Phox2b, a
master gene of sympathetic neuron development, followed by Ascl1, Insm1, Hand2, Phox2a,
Gata2, and Gata3. AP-2β is also important for sympathetic progenitor survival, while Hox genes
for the patterning of the sympathetic chain [33]. Noradrenergic differentiation of sympathetic
progenitors starts after stopping the migration in the vicinity of the dorsal aorta and is reflected
by the expression of tyrosine hydroxylase (TH), followed by dopamine-beta-hydroxylase
(DBH) [34] and pan-neuronal markers. However, these sympathetic neurons are immature
and continue to proliferate in the sympathetic ganglia primordia under the control of a number
of extrinsic signals, such as insulin-like growth factor I (IGF-1), artemin, WNTs, midkine, and
BDNF (reviewed in [31]).
The vast majority of postmitotic sympathetic neurons are generated by asymmetric divisions
of immature neurons, leading to a postmitotic neuron and an immature neuron that is able to
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divide again [35]. Transcription factor codes that underlie the specification and sequential
generation of different sympathetic neuron classes are still not known. However, a large
proportion of transcription factors involved in the initial specification of sympathetic neurons
are expressed up to the adult stage, such as Phox2b, and even selectively expressed in adult
noradrenergic neurons, such as Hand2 [36]. These results demonstrate that several members
of the gene regulatory network that controls initial sympathetic neuron development are also
essential for the maintenance of differentiated neurons.
Survival and terminal differentiation of sympathetic neuron subtypes, as like of sensory
neurons, is controlled by target-derived neurotrophic factors. Their terminal differentiation is
controlled by specific retrograde signaling, which can result in a change of neuropeptide and
neurotransmitter phenotype. For example, sweat glands and periosteum are innervated
postnatally by noradrenergic sympathetic neurons that transdifferentiate to functional
cholinergic sympathetic neurons [37,38].
3.3. Parasympathetic neurogenesis
Different parasympathetic neurons are generated from cranial, vagal, and sacral neural crest
(Figure 2). The development of parasympathetic neurons is controlled by mechanisms that are
closely related to those acting in the sympathetic neuron lineage, but also shows some
interesting differences [31,39,40]. Signals and molecular pathways controlling the specification
and differentiation of parasympathetic neurons have been characterized in detail for the ciliary
ganglion derived from cranial neural crest and for the enteric neurons arriving from the vagal
neural crest.
For the cranial neural crest, BMP5 and BMP7 are expressed at the site of autonomic ganglion
formation and are shown to be essential and sufficient for ciliary neuron development. The
ciliary ganglion and other parasympathetic ganglia, like the sympathetic ganglia, depend on
Ascl1 and Phox2b expression [41,42]. Unlike in the sympathetic lineage, parasympathetic
neuron precursors do not express Gata3, AP-2β and Hox genes. A transient expression of
noradrenergic characteristics (like TH and DBH) is observed, which is maintained in a very
small subpopulation of cells. The majority of cells acquire a cholinergic phenotype, character‐
ized by the expression of choline acetyltransferase (ChAT) and vesicular acetylcholine
transporter (VAChT). For the cranial parasympathetic ganglia, as for the DRGs and in contrast
to sympathetic ganglia, neuron differentiation starts after withdrawal from the cell cycle
[31,41]. However, some postmitotic neurons in the ciliary ganglion do not start to differentiate
after cell cycle exit but rather remain as quiescent postmitotic neuron progenitors that later
differentiate to mature neurons [42].
Recent exciting work has shown that Schwann cell progenitors in the developing cranial nerve
can generate parasympathetic neurons [43,44]. Thus, the developing cranial nerve appears to
serve as both a guide and source of progenitors for the parasympathetic ganglia it will
eventually innervate.
Detailed analysis revealed that both parasympathetic ganglia arise from cells that accompany
the cranial nerve fibers as they grow towards the site of parasympathetic ganglion formation.
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These migratory cells express SOX10, which indicates their crest origin, and additionally is a
marker for Schwann cells [45–47]. During their migration, however, they turn on the expres‐
sion of Phox2b, characteristic for autonomic neurons. These be-fated precursor cells are not
restricted to cranial nerves but are also found in developing limb nerves where they generate
small ganglia composed of Phox2b neurons. It is yet unclear which signals control the fate
switch in the migration bi-fated precursor cells and how progenitors become restricted to a
parasympathetic fate rather than to a sympathetic neuronal fate.
3.4. Enteric neurogenesis
The ENS develops from both the vagal and sacral neural crest. Vagal neural crest generates
most of the ENS and migrates caudally to colonize the entire length of the bowel. Vagal neural
crest acquires the ENS formation ability after further programming during migration to the
foregut. This involves signaling by Hedgehog and retinoic acid systems which upregulate Ret
expression of vagal neural crest. Enteric neuron precursors express Phox2a and TRKC. The
mechanisms generating the large diversity of neurotransmitter phenotypes, including
serotonin (5-hydroxytryptamine, 5-HT), GABA (γ-aminobutyric-acid-positive) and nitric-
oxide-synthase (NOS)-positive neurons, are not yet known [39, 40].
4. Peripheral neurogenesis in vitro
4.1. Neural crest and placode induction protocols
During the last 15 years, many protocols for generating different neural progenitors and
neurons from hESCs were developed. The early methods to differentiate human PSCs towards
neural lineages were focused on producing neural stem cells and some CNS derivatives,
whereby neural crest cells were observed as a by-product of neural differentiation. Some of
these protocols involved dense self-organizing cell conglomerates, such as embryoid bodies,
neural rosettes, or confluent cultures, that produce undefined signaling [48,49], while other
protocols relied on the use of stromal feeder co-cultures [50,51]; however, these undefined
protocols were not able to generate more than 10% of cells with neural crest identity.
A step forward in the increasing efficiency of neural induction in hPSCs was the introduction
of the “dual SMAD inhibition” protocol, which generated high yields of neuroectodermal cells
and CNS fates. This protocol uses the concomitant inhibition of BMP pathway with Noggin
and of TGFβ/activin/Nodal signaling pathway with SB431542 (SB) [5]. Based on this protocol,
different strategies were developed to direct the neuroectoderm cell towards neural crest cells,
using dual SMAD inhibition and WNT signaling [52–54]. Most of them used the small molecule
CHIR99021 (CHIR) to enhance WNT/β-catenin signaling by inhibiting GSK3β. Other protocols
were able to generate more neural crest cells by using the WNT agonist CHIR and only the
TGFβ/activin/Nodal receptor inhibitor, but not BMP inhibitors [55, 56]. The efficiency of these
protocols was variable, and additional separation methods were implemented to increase the
neural crest yield, relying on surface markers such as HNK1 (human natural killer-1) and
p75NTR (NGFR) [52–56].
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A very recent protocol [57] dramatically improved the yield of neural crest cells in defined
serum free-media under WNT activation by simply eliminating both the BMP inhibitor noggin
and the TGFβ/activin/Nodal receptor inhibitor SB. This study established a rapid (5 days) and
efficient protocol for generating a high yield of neural crest cells. This approach significantly
shortens the total length of time required for the neural crest induction. At day 5, the differ‐
entiating cells expressed in high proportion (more than 80%) the neural crest markers SOX10,
PAX7, and TFAP2A. Additionally, it was clearly demonstrated with this protocol that blocking
the FGF and BMP pathways or increasing FGF and BMP activity dramatically decreased the
neural crest induction (below 5% of the total cell population).
Another recent report [58] demonstrated that de-repression of endogenous BMP signaling
during dual SMAD inhibition is sufficient for the selective induction of human cranial placode
cells. Gene expression analysis at day 11 revealed, upon withdrawal of Noggin at day 2 or 3 of
differentiation, a robust induction of the preplacodal markers SIX1, EYA1, and DLX3, and
more than 70% of cells adopting a SIX1+ cranial placode fate.
Leung et al. [57] also investigated the cranial placode induction in the same defined culture
conditions as for neural crest induction, but without CHIR. They found that E-cadherin, and
preplacodal markers such as EYA2, FOXC1 and ISL1 were highly induced in day 5 cultures.
Upon CHIR administration, however, these surface ectoderm and preplacodal transcripts
were repressed.
The capacity of human neural crest and placode-like cells generated with different protocols
to contribute to terminal derivatives associated with neural crest and placode development
was tested in different approaches. Most of the neural crest-like cells were tested for their
multipotency and were subjected to terminal differentiation into different derivatives,
including sensory neurons, sympathetic neurons, enteric neurons, Schwann cells, melano‐
cytes, chondrocytes, and osteoblasts. The placode-like cells were tested for their competence
to generate sensory neurons, lens cells, and hormone-producing anterior pituitary cells [58].
Early protocols were based mainly on spontaneous differentiation, identifying different
proportion of specific derivatives such as sensory neurons (Brn3a+/periferin+), sympathetic
progenitors (TH+/periferin+), glial precursors (S100β+ GFAP+/−), and melanoblasts (MITF+
SOX10+). Some recent protocols were designed for the generation of sensory and enteric
neurons, which are briefly presented below.
4.2. Sensory neuronal differentiation protocols
Human NCCs generated peripheral sensory neurons as well as other neural crest derivatives
applying different protocols. For peripheral neuronal differentiation, NCCs were plated on a
special coated surface in order to facilitate neuronal growth (such as Matrigel or Geltrex-coated
plates, lanimin/fibronectin or collagen), followed by a treatment with a cocktail of neurotrophic
molecules to sustain sensory neuronal differentiation and maturation: brain-derived neuro‐
trophic factor (BDNF), neurotrophin-3 (NT-3), and nerve growth factor (NGF). Markers
associated with peripheral sensory neurons (PRPH BRN3a, and ISL1,) and glial progenitors
(S100β) were detected after 7–14 days [48–53, 56–61].
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Chambers et al. [59] applied another protocol which resulted in the highly efficient derivation
of human nociceptive neurons from PSCs within a short period of time. Specification into
nociceptive neurons was achieved by adding an inhibitor of tyrosine kinase signaling
(SU5402), a blocker of the NOTCH signaling (such as M N-[N-(3,5-difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester, DAPT, which blocks γ-secretase) and a GSK-3β inhibi‐
tor (CHIR), which promotes WNT/β-catenin signaling [59–61].
The differentiation of neural crest cells toward a sensory phenotype was marked by the
expression of the pro-neural transcription factors NGN2 and NGN1. Also consistent with early
sensory neurogenesis, the expression levels of PRPH, BRN3A, ISL1 were found to be highly
up-regulated. The majority of neurons derived from all iPSC lines co-expressed BRN3A and
PRPH, a combination that had been shown to be specific for peripheral sensory neurons in
vivo. Most of the PRPH positive cells co-expressed ISL1, another recognized markers of sensory
specification [23–25].
The increasing expression of the glutamatergic markers VGLUT1 and VGLUT2 as well as very
low expression levels of markers for non-sensory neuronal phenotypes (such as MASH1, HB9,
DBH, GAD, and VACHT) additionally supported an efficient sensory specification. The
increasing expression of the synaptic marker SYNAPTOPHYSIN (SYP) indicated that the
neurons were maturing to become functional. These newly differentiated neurons up-
regulated markers of proprioceptive (TRK C, RUNX3), nociceptive (TRK A, RUNX1), or
mechanoceptive (TRK B) subtypes.
Optimization of long-term differentiation will be necessary in order to sustain the matura‐
tion and subtype specification in vitro.
4.3. Autonomic neuronal differentiation protocols
A very recent study [62] describes an efficient strategy to derive enteric neurons with vagal
origin and cranial parasympathetic neurons from human ESCs, based on CHIR and the dual
SMAD neural crest induction protocol. Enteric neuron specification involves additional
treatment with retinoic acid from day 6 to day 11. The differentiated cells were sorted for
CD49D at day 11. ENC cells from the 11 day induction protocol were aggregated into 3D
spheroids and cultured in defined medium containing CHIR and FGF2. After 4 days of
suspension culture, the spheroids were plated on poly-ornithine/laminin/fibronectin-coated
dishes in medium containing GDNF. The enteric neuron precursors migrated out of the plated
spheroids and differentiated into neurons in 1–2 weeks, further maturing for up to 60 days.
Purified CD49D+ precursors, derived in the presence of retinoic acid, expressed HOXB2–
HOXB5 indicative of vagal identity, but not more caudal HOX transcripts such as HOXB9. In
further agreement with vagal identity, CD49D+, retinoic-acid-treated neural crest precursors
expressed markers of early enteric lineages including PAX3, EDNRB and RET. Replating 3D
spheroids under differentiation conditions yielded immature neurons expressing TUJ1 and
the enteric precursor marker PHOX2A and ASCL1 (day 20). Most PHOX2A+ cells were positive
for TRKC a surface marker expressed in enteric neuron precursors. Temporal expression
analyses showed maintenance of ENC neuronal precursor marker expression by day 40 of
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differentiation, followed by an increase in the percentage of mature neurons by day 60. In
agreement with enteric neuron identity, a broad range of neurotransmitter phenotypes was
observed, including serotonin-positive (5-hydroxytryptamine+, 5-HT+), GABA+ (γ-aminobu‐
tyric-acid-positive), and nitric-oxide-synthase-positive (NOS)+ neurons.
The CD49D+ crest progenitors not treated with RA were HOX-negative, expressing a cranial
autonomic phenotype. CNC-derived precursors differentiated into tyrosine-hydroxylase-
expressing neurons and gave rise to TRKB-positive rather than TRKC-positive precursors, and
no 5-HT+ neurons were observed [62].
5. From in vitro differentiation of PSCs to human PNS development and
diseases
5.1. An in vitro neuronal differentiation model
Based on the recent reports presented above, a model for neuronal differentiation is pro‐
posed here (Figure 3). HESCs resemble epiblast cells in terms of signaling requirements and
gene regulatory network for self-renewal and maintenance. Combining various chemically
defined conditions, cell plating strategies, and activation of signaling pathways, such as
activin, Nodal, FGF, and WNT, can direct the differentiation of hESCs into a number of cell
Figure 3. An in vitro model of human pluripotent stem cell (hPSC) neuronal differentiation. This model is based on
recent PSC-derived protocols and in vivo expression data and depicts the stage-wise in vitro differentiation of hPSC
toward neural progenitor cells, neural crest cells, preplacodal cells, and different classes of neurons. NCCs, neural crest
cells; NNCs, non-neural cells; PPCs, preplacodal cells; NBCs, neural border cells; NECs, neuroepithelial cells; NPCs,
neural progenitor cells.
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types, including the ones generating neural plate, neural crest and placodes. As in develop‐
ment, different peripheral neurons can be generated from regionally patterned neural plate,
neural crest, and cranial placode-like cells.
Through the blocking of BMP, activin, and Nodal (via dual SMAD inhibition), hPSCs loose
stemness/pluripotency markers and acquire characteristics of neuroepithelial cells (NECs) and
further neural progenitor cells (NPCs) and CNS neuronal types. Through the WNT activa‐
tion (via GSK3 inhibition with small molecules such as CHIR), hPSCs acquire characteristics
of non-neural ectodermal cells, neural border cells and neural crest cells. In the absence of WNT
activity, markers associated with non-neural ectoderm, placodal and epidermal tissues arise.
All these steps are characterized by batteries of transcription factors which are in accordance
with the pan-vertebral model. This model relies on milestone-markers which have been
identified in a specific fashion in embryonic human NC [63].
In the specification and differentiation steps, including further treatment with CHIR, the NCCs
acquire a cranial phenotype, generating mainly cranial parasympathetic neurons. Addition‐
al patterning of NCCs with CHIR and RA allows the generation of enteric neurons and DRG
sensory neurons. For sensory differentiation, FGF signaling should be blocked (with the
inhibitor SU). Placode precursors generate mainly sensory neurons with a trigeminal pheno‐
type. For all the neuronal differentiation steps, blocking NOTCH signals with DAPT dramat‐
ically increases the neuronal yield.
5.2. Modeling human early development
For obvious reasons, neural crest and placode development, as well as the sensory and
autonomic neurogenesis, are difficult to be studied in human embryos. Access to gastrula stage
embryos is extremely limited, and their experimental manipulation almost impossible.
Nevertheless, neural crest marker expression patterns have been studied at various develop‐
mental stages [63]. However, no study in human embryos related the earliest events occur‐
ring during gastrulation and at the onset of neurulation.
The newly devised protocol using hPSC differentiation will certainly facilitate future studies
on human PNS development. It is already the case in the same very recent study [57],
demonstrating that in early human development, the earliest NC populations arise independ‐
ently of neural and mesodermal tissues, from precursors that precede the standard neural plate
border characteristics. By examining the expression dynamics of a number of neural-related
transcripts, no correlation for the induction of PAX6+ NECs and SOX10+ NCCs was found.
Furthermore, knockdown assays also suggested that reduced PAX6 function did not nega‐
tively interfere with NC induction. These recent data substantiate the notion that human NC
forms independently of PAX6+ neuroectoderm. An early origin of human NCCs independ‐
ent of neural progenitors has been suspected, in accordance with the recent embryological
evidence has also suggested the capacity of non-neural ectoderm to form NC without acquiring
a neural character (see section 2).
Neural induction in hESCs requires inhibition of either BMP or activin, or both [5]. The fact
that administration of noggin blocked expression of NC and/or neural border markers suggests
Pluripotent Stem Cells - From the Bench to the Clinic320
that human NC induction requires BMP activation, which is distinct from neural induction. It
is also worth noting that transcripts for BMP ligands can be readily detected under CHIR
treatment, supporting the suggested contribution of this pathway during later events in NC
development, such as sensory and autonomic differentiation.
5.3. Human peripheral neurons and their application in medicine
The availability of hPSCs can provide not only a source for investigating the early human
development, but also a source for generating human neurons for in vitro studies. Obviously,
human neurons are difficult or impossible to be obtained from adult tissue, in primary culture,
as it is the case for many other cells (e.g., blood cells, fibroblasts, skin cells). Many functional
approaches can be performed with hESC-derived peripheral neurons, such as the electrophy‐
siological investigation of different human neurons in vitro [64]. Many compounds can be
tested for their neurotoxicity using assays based on human peripheral neurons, together with
other central neurons [60].
In particular, specific neuronal subtypes generated from the patient iPSCs have become a
source for studying disease mechanisms underlying different neurological disorders from
which the affected neurons were not possible to be available before. The patient-derived in
vitro models can recapitulate the disease in a dish, for determining its etiology and progres‐
sion and could develop into a key drug discovery platform. During recent years, the genera‐
tion of iPSC lines from human material has become routine. Even more, high-quality iPSCs
obtained with non-integrative methods and the complete epigenetic resetting were reported
[65]. This brings the iPSCs more close to the clinics, increasing their potential for use in
regenerative medicine.
Protocols for sub-types of neurons with different degrees of heterogeneity are currently being
used for different peripheral neuropathies (PNPs). Recent studies proved the utility of iPSC-
derived neural crest cells and peripheral neurons for neurocristopathies (NCPs) and neuro‐
degenerative diseases (NDDs).
NCPs are a major group of human congenital disorders caused by neural crest developmen‐
tal deficiencies. To better understand the etiology of NCPs and perhaps identify targets for
therapeutic intervention, it is critical to understand the detailed mechanisms of neural crest
specification, migration, and differentiation in human embryos. The most common NCPs in
which the peripheral neurons are affected are familial dysautonomia (FD) and Hirschsprung
disease (HiD).
A first example is provided in a study using hiPSCs derived from FD patients, a pathology
characterized by the degeneration of sensory and autonomic neurons [66]. Most FD patients
carry a point mutation in the IKBKAP gene (I-k-B kinase complex associated protein), leading
to a tissue-specific splicing defect, resulting in reduced levels of normal IKBKAP protein.
Neural crest precursors obtained in vitro from FD hiPSCs show low levels of normal IKB‐
KAP transcript, defective neuronal migration, and differentiation. These characteristics were
used to monitor the effects of various drugs on NC-induced hiPSCs and have validated a
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compound restoring the IKBKAP splicing defect in these cells. These compounds rescue IKAP
protein expression and the disease-specific loss of autonomic neuron marker expression [66].
Another example is HiD, in which the enteric neuron progenitors fail to colonize the full length
of the bowel during early development. To investigate possible therapies for the HiD, a very
recent study used hPSC in vitro under conditions that encouraged them to differentiate into
cells resembling ENS precursors [62]. These progenitors were further transplanted into the
colons of mice with a genetic mutation that causes a Hi-like disease. The transplant prevent‐
ed premature death in these mice, although how the cells achieved this condition is not clear.
Finally, hiPSC-derived ENS precursors enable the identification of candidate therapeutic
targets [62]. In this case, the cell-based therapy can transform the future of patients with severe
phenotype such as total intestinal aganglionosis.
In another class of PNP, specific peripheral neurons are affected by a neurodegenerative
process. It is the case of Friedrich Ataxia (FRDA), an autosomal-recessive disease caused by a
GAA triplet expansion in the first intron of the Frataxin (FXN) gene [67]. Major neuropatho‐
logic findings comprise a degeneration of DRGs, with loss of large sensory neurons, fol‐
lowed by cerebellar and cardiomyocytes degeneration. FRDA-iPSC lines have been established
and were successfully differentiated into sensory neurons [67], as well as cardiomyocytes [68].
So far, no overt phenotype was observed in iPSC-derived neurons in FRDA in contrast to the
reported mitochondrial phenotype in FRDA-iPSC-derived cardiomyocytes [67,68]. However,
during the differentiation process of FRDA iPSCs to peripheral neurons via generation of
neural crest cells, a differential expression of the frataxin protein was observed between control
and FRDA iPSCs, with the FRDA sensory neurons lacking the up regulation found in control
neurons. One limitation of this model is related to the maturity of neurons derived from iPSCs.
Most iPSC-derived neurons seem to more closely resemble embryonic neurons than mature
and aged neurons, and long-time cultures are required to model non-congenital disorders;
additionally, it may be necessary to devise protocols that favor aging and degeneration-
associated features [69].
To fully tap into the potential of the iPS technology and to progress toward a fundamental
understanding of the causes of disease selectivity in the loss of neuron subtypes, it is necessa‐
ry to establish reproducible and tailored protocols for differentiation of iPSCs specifically into
these neuronal subtypes in vitro.
Better identification of a dysfunctional pathway in patients suffering from complex PNPs is
the primary requirement for rational therapeutic drug development. The human iPSC-derived
models could impact positively the screening of compound libraries and the drug safeties
screens and in the same time reduce the animal dependency of the current drug develop‐
ment pipeline. iPSC technology is seen as an important driver of personalized medicine. Prior
to treatment, patient-derived iPSCs or differentiated progenies can be used to tailor a particular
drug type and dose according to the genetic and cellular profile. Based on all these facts, the
hPSC-based PNS platform will allow the development of cell- and drug-based strategies for
the treatment of different PNS diseases.
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The most promising aspect of patient-derived cellular models is the idea of curing genetic
diseases in vitro. Hence, patient donor cells (like fibroblasts) could be genetically corrected,
reprogrammed into iPSCs and further differentiated into the desired progenitor cell. Another
possibility is to generate isogenic iPSC lines by genetic modifications through target specific
CRISPR/Cas9 technologies [70].
6. Conclusions
hPSCs have provided a revolutionary impact on modeling human PNS development,
pathophysiology of different PNPs as well as on novel therapies for them. In the last few years,
major efforts have been made to use hPSC to bypass the difficulties linked to working on the
human embryo. The knowledge accumulated by embryologists working on various verte‐
brate model organisms has allowed the development of several strategies to manipulate cell
fate choices from stem cells grown in vitro. These new in vitro cellular models have provided
insights into the steps underlying determination and differentiation of diverse neural crest and
placode cell lineages. Additionally, recent studies showed that it is now possible to differen‐
tiate patient-derived iPSCs into disease-susceptible neuronal phenotypes. The experiments
described here proved the presence of disease-inherent phenotypes in iPSCs and the iPSC-
derived affected neurons and even revealed new pathophysiological insights and promising
candidate substance testing in some PNPs.
However, a lot of work is still needed to optimize and integrate the specific differentiation
protocols in the disease-related iPSC models. More importantly, these need to be translated in
vivo for all the PNPs, and a better appreciation of the precise signals and switches that dictate
the survival, proliferation, and differentiation of neural crest cells into their distinct deriva‐
tives will facilitate their application in therapeutic and regenerative medicine. Nevertheless,
patient iPSC-derived neurons provide a unique opportunity to gain insights into the patho‐
physiology of PNPs, as well as for drug screening, cell therapy, and personalized medicine.
As presented above, the in vitro derivation of PNS lineages from human PSCs did not achieve
the same tremendous progress as of CNS lineages, despite the great medical needs also for
peripheral neurons. However, the very recent progress in deriving human NCCs, placode cells,
and enteric neurons marked a new stage in the human PNS development and diseases.
However, understanding the programs of peripheral neurogenesis, especially in the later
developmental stages, is a major challenge confronting development biologists in years to
come.
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